Brokerages predict that GTx, Inc. (NASDAQ:GTXI) will post ($0.39) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for GTX’s earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.41). GTX reported earnings of ($0.44) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 11.4%. The business is expected to report its next earnings results on Wednesday, March 21st.

According to Zacks, analysts expect that GTX will report full-year earnings of ($1.61) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($1.48). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.68) per share, with EPS estimates ranging from ($1.69) to ($1.66). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for GTX.

GTX (NASDAQ:GTXI) last posted its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25).

Several research analysts have recently weighed in on the company. Zacks Investment Research raised GTX from a “sell” rating to a “hold” rating in a research report on Wednesday. Robert W. Baird initiated coverage on GTX in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $17.00 target price for the company. Finally, Stifel Nicolaus initiated coverage on GTX in a research note on Thursday, November 9th. They issued a “buy” rating for the company.

GTX (NASDAQ GTXI) opened at $12.16 on Wednesday. GTX has a 12-month low of $2.73 and a 12-month high of $13.35. The firm has a market capitalization of $258.07, a PE ratio of -6.95 and a beta of 1.77.

In other news, CEO Marc Steven Hanover sold 7,309 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $11.33, for a total value of $82,810.97. Following the completion of the sale, the chief executive officer now directly owns 129,990 shares in the company, valued at approximately $1,472,786.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jason T. Shackelford sold 3,090 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $11.33, for a total value of $35,009.70. Following the completion of the sale, the insider now owns 31,111 shares of the company’s stock, valued at $352,487.63. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,364 shares of company stock valued at $174,074. 41.20% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in shares of GTX in the 2nd quarter valued at about $124,000. Caxton Corp acquired a new stake in shares of GTX in the 3rd quarter valued at about $531,000. Finally, Abingworth LLP acquired a new stake in shares of GTX in the 3rd quarter valued at about $2,781,000. Institutional investors own 11.57% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Anticipate GTx, Inc. (GTXI) Will Post Earnings of -$0.39 Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/17/zacks-brokerages-anticipate-gtx-inc-gtxi-will-post-earnings-of-0-39-per-share.html.

About GTX

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Get a free copy of the Zacks research report on GTX (GTXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.